ATE275976T1 - Chimäre toxine enthaltend gnrh zur zielgerichteten therapie - Google Patents

Chimäre toxine enthaltend gnrh zur zielgerichteten therapie

Info

Publication number
ATE275976T1
ATE275976T1 AT97925249T AT97925249T ATE275976T1 AT E275976 T1 ATE275976 T1 AT E275976T1 AT 97925249 T AT97925249 T AT 97925249T AT 97925249 T AT97925249 T AT 97925249T AT E275976 T1 ATE275976 T1 AT E275976T1
Authority
AT
Austria
Prior art keywords
cells
chimeric toxins
neoplastic cells
moieties
relates
Prior art date
Application number
AT97925249T
Other languages
English (en)
Inventor
Shai Yarkoni
Amotz Nechushtan
Haya Lorberboum-Galski
Irina Marianovski
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Application granted granted Critical
Publication of ATE275976T1 publication Critical patent/ATE275976T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
AT97925249T 1996-06-04 1997-06-04 Chimäre toxine enthaltend gnrh zur zielgerichteten therapie ATE275976T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL118570A IL118570A (en) 1996-06-04 1996-06-04 Use of a chimeric protein that includes Met – GnRH in the preparation of a pharmaceutical preparation for the treatment of adenocarcinoma or patocarcinoma
PCT/IL1997/000180 WO1997046259A2 (en) 1996-06-04 1997-06-04 Chimeric toxin for targeted therapy

Publications (1)

Publication Number Publication Date
ATE275976T1 true ATE275976T1 (de) 2004-10-15

Family

ID=11068929

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97925249T ATE275976T1 (de) 1996-06-04 1997-06-04 Chimäre toxine enthaltend gnrh zur zielgerichteten therapie

Country Status (12)

Country Link
US (3) US6933271B2 (de)
EP (1) EP1007095B1 (de)
JP (1) JP4067123B2 (de)
KR (1) KR20000016369A (de)
AT (1) ATE275976T1 (de)
AU (1) AU735813B2 (de)
DE (1) DE69730747T2 (de)
DK (1) DK1007095T3 (de)
ES (1) ES2229358T3 (de)
IL (1) IL118570A (de)
PT (1) PT1007095E (de)
WO (1) WO1997046259A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL116436A (en) 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND
IL118570A (en) * 1996-06-04 2007-06-17 Shai Yarkoni Use of a chimeric protein that includes Met – GnRH in the preparation of a pharmaceutical preparation for the treatment of adenocarcinoma or patocarcinoma
US6635740B1 (en) 1997-03-27 2003-10-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Ligand/lytic peptide compositions and methods of use
US8962558B2 (en) 1997-07-04 2015-02-24 Johannes C. van Groeninghen Methods for reducing GnRH-positive tumor cell proliferation using the GnRH antagonist IN3
DE19728737C1 (de) * 1997-07-04 1999-02-11 Johannes Christian Groeninghen Verfahren zur Erkennung und Bestimmung von GnRH-Rezeptoren und die Verwendung von GnRH-Agonisten und GnRH-Antagonisten zur Behandlung eines Tumors ausgehend vom Hirn und/oder Nervensystem und/oder den Hirnhäuten
US6680058B1 (en) 1997-09-03 2004-01-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for contraception in or sterilization of mammals
US6140066A (en) * 1998-03-24 2000-10-31 Lorberboum-Galski; Haya Methods of cancer diagnosis using a chimeric toxin
JP2002526422A (ja) * 1998-10-02 2002-08-20 ウィンディー ヒル テクノロジー インコーポレイテッド 乳癌の同定、診断、及び治療の方法
US20030022383A1 (en) * 1999-04-06 2003-01-30 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
JP2004535202A (ja) * 2001-07-17 2004-11-25 リサーチ　ディベロップメント　ファンデーション アポトーシス促進性蛋白質を含む治療剤
KR100808735B1 (ko) * 2006-11-04 2008-02-28 진은철 황체호르몬 분비호르몬 및 독소분자의 복합체를유효성분으로 하는 건선 예방 및 치료제
JP2010154842A (ja) 2008-12-03 2010-07-15 Koji Kawakami Ｅｇｆｒを標的にした新規抗がんキメラペプチド
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215051A (en) * 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4902495A (en) * 1986-07-22 1990-02-20 The United States Of America As Represented By The Department Of Health And Human Services IgE Fc directed delivery system
US5082927A (en) * 1986-09-24 1992-01-21 The United States Of America As Represented By The Department Of Health And Human Services Selectively cytotoxic IL-4-PE40 fusion protein
AU5186090A (en) * 1989-02-23 1990-09-26 Colorado State University Research Foundation Gnrh analogs for destroying gonadotrophs
US5458878A (en) * 1990-01-02 1995-10-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity
DK0531434T3 (da) * 1990-05-11 2000-01-31 Us Health Forbedrede Pseudomonas-exotoksiner med lav dyretoksicitet og høj cytocidal aktivitet
DE4122530A1 (de) * 1991-07-08 1993-01-14 Henkel Kgaa Verfahren zur herstellung von fettsaeureniedrigalkylestern
US5723129A (en) * 1991-10-16 1998-03-03 University Of Saskatchewan GnRH-leukotoxin chimeras
US5837268A (en) * 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
US5382660A (en) * 1991-10-25 1995-01-17 The University Of Tennessee Research Corporation TcpG gene of vibrio cholerae
AU3665293A (en) 1992-02-14 1993-09-03 Merck & Co., Inc. Chimeric toxins binding to the GnRH receptor
WO1993025690A1 (en) * 1992-06-18 1993-12-23 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Recombinant pseudomonas exotoxin with increased activity
US5672686A (en) * 1994-08-09 1997-09-30 Immunogen, Inc. Bcl-Y - specific antibodies
US5759782A (en) * 1995-06-07 1998-06-02 The United States Of America Cellular apoptosis susceptibility protein (CSP) and antisense CSP
IL116436A (en) * 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND
US6008042A (en) * 1996-05-16 1999-12-28 Smithkline Beecham Corporation Interleukin-1 beta converting enzyme like apoptotic protease-7
US5834234A (en) * 1996-05-29 1998-11-10 Immunogen, Inc. Apoptosis associated protein Bbk
IL118570A (en) * 1996-06-04 2007-06-17 Shai Yarkoni Use of a chimeric protein that includes Met – GnRH in the preparation of a pharmaceutical preparation for the treatment of adenocarcinoma or patocarcinoma
US6218363B1 (en) * 1996-08-28 2001-04-17 Thomas Jefferson University MHC peptides and methods of use
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US6645490B2 (en) * 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
US6140066A (en) * 1998-03-24 2000-10-31 Lorberboum-Galski; Haya Methods of cancer diagnosis using a chimeric toxin

Also Published As

Publication number Publication date
US6933271B2 (en) 2005-08-23
AU735813B2 (en) 2001-07-19
ES2229358T3 (es) 2005-04-16
US20090181894A1 (en) 2009-07-16
IL118570A (en) 2007-06-17
US20050256049A1 (en) 2005-11-17
DE69730747T2 (de) 2005-09-22
IL118570A0 (en) 1996-10-16
WO1997046259A3 (en) 1998-03-12
WO1997046259A2 (en) 1997-12-11
PT1007095E (pt) 2005-01-31
DK1007095T3 (da) 2005-01-24
EP1007095A2 (de) 2000-06-14
DE69730747D1 (de) 2004-10-21
AU3045297A (en) 1998-01-05
US20020028914A1 (en) 2002-03-07
EP1007095B1 (de) 2004-09-15
KR20000016369A (ko) 2000-03-25
JP2000511431A (ja) 2000-09-05
JP4067123B2 (ja) 2008-03-26

Similar Documents

Publication Publication Date Title
DE69730747D1 (de) CHIMÄRE TOXINE ENTHALTEND GnRH ZUR ZIELGERICHTETEN THERAPIE
NZ285159A (en) Treatment of benign prostatic hyperplasia, endometriosis, prostatic carcinoma and obesity by administration of droloxifene
BR0009445A (pt) Utilização de um extrato lipìdeo-esterólico de serenoa repens
IL130823A (en) Peptide-lipid conjugates, liposomes drug delivery
WO2001082961A3 (en) Methods for treating bone tumors
WO1997029779A3 (en) EGF-Genistein conjugates for the treatment of cancer
MXPA02011379A (es) Ensayo de deteccion de genes para mejorar la probabilidad de una respuesta efectiva a terapia de cancer con el antagonista erbb.
BR0110421A (pt) Polipeptìdeos anti-angiogênicos e métodos para inibir a angiogênese
MXPA04003514A (es) Construcciones de polinucleotidos, composiciones farmaceuticas y metodos para reducir la regulacion dirigida de angionesis y terapia anticancer.
IL138655A0 (en) Methods of cancer diagnosis using a chimeric toxin
NZ504938A (en) Tumor antigen peptide derivatives capable of binding to HLA-A24 antigen
WO2000053219A3 (en) Compositions and methods for treating cancer and hyperproliferative disorders
BR9914794A (pt) Laxativo osmótico, não fermentado, para tratar e prevenir o câncer cólon-retal
WO2000057911A3 (en) Hapten-conjugated mammalian cells and methods of making and using thereof
WO2003026580A3 (en) Interactive therapeutic enclosures
ATE313334T1 (de) Behandlung von tumoren mit photodynamischer therapie
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
ATE462441T1 (de) Saposin c und rezeptoren als ziele für die behandlung von gutartigen und bösartigen erkrankungen
WO2001053524A3 (en) Cancer associated genes and their products
Walker et al. Monoclonal antibody mediated intracellular targeting of tallysomycin S10b
NO995109L (no) Formuleringer inneholdende 1,2,4-benzotriazinoksyder
ATE240100T1 (de) Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten
WO2001090159A3 (en) Compositions and methods for delivery of a molecule into a cell
Jones et al. Towards enzyme activated antiprostatic agents
Snider et al. c-erbB-2/p185-directed therapy in human lung adenocarcinoma

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1007095

Country of ref document: EP

REN Ceased due to non-payment of the annual fee